Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naive first episode psychosis patients aged 15 to 25 years.

Trial Profile

A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naive first episode psychosis patients aged 15 to 25 years.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Psychotic disorders
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Jan 2011 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 18 May 2007 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top